Anemia in breast cancer patients reduced by epoetin alfa with no negative impact on survival

In patients with high-risk breast cancer, addition of the erythropoiesis-stimulating agent (ESA) epoetin alfa to the chemotherapy regimen may help avoid the decrease in hemoglobin levels and resulting anemia often seen in these patients and does not negatively affect relapse-free (RFS) or overall survival (OS). However, it can increase the risk of thrombotic events, according to a study published in the Journal of the National Cancer Institute. To investigate the safety and efficacy of epoetin alfa, Volker Moebus, M.D...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Breast Cancer Source Type: news